A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease.
Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, Olszewski AJ, Arnason JE, Ahn IE, Brown JR.
Davids MS, et al. Among authors: ren y.
J Clin Oncol. 2024 Dec 7:101200JCO2402503. doi: 10.1200/JCO-24-02503. Online ahead of print.
J Clin Oncol. 2024.
PMID: 39645236